Press release from Business Wire
ARIAD to Present at the 31st Annual Cowen Healthcare Conference
Monday, February 28, 2011
CAMBRIDGE, Mass. (Business Wire) -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 31st annual Cowen Healthcare Conference being held at the Boston Marriot Copley Place in Boston, Massachusetts. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide an overview of the Company's robust oncology pipeline and progress on its three lead compounds on Monday, March 7, at 10:35 a.m. (ET).
The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor. A replay of the presentation will be available on the ARIAD website approximately one hour after the presentation and will be archived for two weeks.
ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck that has successfully completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being studied in multiple cancer indications. ARIAD's second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information, please visit www.ariad.com.
ARIAD Pharmaceuticals, Inc.
Maria E. Cantor, 617-621-2208